BACE1 and Alzheimer disease: Intravenous administration of rabies virus glycoprotein (RVG)-modified DC-derived EVs loaded with therapeutic BACE1-targeting siRNA in mice inhibited BACE1 expression in the brain, a potential therapeutic target for AD [14].